Advertisement
Advertisement
U.S. Markets closed
Advertisement
Advertisement
Advertisement
Advertisement

CareDx, Inc (CDNA)

NasdaqGM - NasdaqGM Real Time Price. Currency in USD
Add to watchlist
26.17+2.10 (+8.72%)
At close: 04:00PM EDT
26.60 +0.43 (+1.64%)
After hours: 07:00PM EDT
Advertisement
Full screen
Trade prices are not sourced from all markets
Gain actionable insight from technical analysis on financial instruments, to help optimize your trading strategies
Chart Events
Neutralpattern detected
Previous Close25.15
Open25.85
Bid10.31 x 800
Ask28.75 x 800
Day's Range24.25 - 26.26
52 Week Range21.25 - 96.88
Volume827,079
Avg. Volume872,725
Market Cap1.382B
Beta (5Y Monthly)0.66
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • GlobeNewswire

    CareDx Receives CE Mark for AlloSeq HCT for Use in Hematopoietic Cell Transplantation

    CareDx Expands Transplant Portfolio in EuropeSOUTH SAN FRANCISCO, Calif., May 24, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that it has received CE marking for its AlloSeq HCT chimerism testing kit and AlloSeq HCT interpretation software for use in patients who have received hematop

  • GlobeNewswire

    CareDx Sponsored ISHLT Innovation Challenge Award Tackles Chronic Lung Allograft Dysfunction

    Donor-Derived Cell-Free DNA will be Used to Evaluate Treatment to Improve Lung Transplant OutcomesSOUTH SAN FRANCISCO, Calif., May 18, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that the International Society for Heart and Lung Transplantation (ISHLT) has selected Dr. Berta Sáez-Gimé

  • GlobeNewswire

    In CareDx-Initiated IP Litigation Against Natera, Natera Now Drops 1 of 2 Patents Originally Asserted Against CareDx

    Natera Recycles Old IP for New Lawsuits SOUTH SAN FRANCISCO, Calif., May 17, 2022 (GLOBE NEWSWIRE) -- CareDx, Inc. (Nasdaq: CDNA) – The Transplant Company™ focused on the discovery, development, and commercialization of clinically differentiated, high-value healthcare solutions for transplant patients and caregivers – today announced that Natera has just dropped one of their two patents originally asserted against CareDx. At the same time, Natera asserted two patents that are variations of the o

Advertisement
Advertisement